Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years
Not Applicable
Completed
- Conditions
- Upper Respiratory Tract Infections
- Interventions
- Drug: Placebo
- Registration Number
- NCT01396889
- Lead Sponsor
- Hormozgan University of Medical Sciences
- Brief Summary
Acute upper respiratory tract infections are the most commmon infections in children and are associated with complications such as acute otitis media, sinusitis and pneumonia. Echinacea is widely used for treatment of upper respiratoty tract infections. The aim of this study is to evaluate its efficacy as prophilaxis in children 1-5 years old.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Childrens 1-5 years old
Exclusion Criteria
- Wheezing in previous 3 months requiring bronchodilatator
- History of hyperactive reactive airway
- using steroid or Echinacea
- chronic pulmonary of cardiac disease
- Acute respiratory disease within one week before study
- Allergic rhinitis
- Allergy to Echinacea
- avoiding to participate in the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Echinacea Echinacea 0.5ml daily for children 1-2 years old and 2ml daily for children2-5 years old for 3 months Placebo Placebo Placebo
- Primary Outcome Measures
Name Time Method occurrence of upper respiratory tract infection diagnosed by physician according to history and physical examination and laboratory tests if was necessary 6 months
- Secondary Outcome Measures
Name Time Method Drug side effects 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Echinacea's prophylactic effects on upper respiratory tract infections in pediatric populations?
How does Echinacea compare to standard-of-care treatments like oseltamivir in preventing upper respiratory tract infections in children aged 1-5?
Are there specific biomarkers that predict Echinacea efficacy in preventing acute otitis media in young children?
What are the potential adverse events associated with Echinacea prophylaxis in pediatric patients and how are they managed?
What combination therapies involving Echinacea have shown promise in reducing the incidence of upper respiratory tract infections in children?
Trial Locations
- Locations (1)
Hormozgan University of Medical Sciences (HUMS)
🇮🇷Bandar Abbas, Hormozgan, Iran, Islamic Republic of
Hormozgan University of Medical Sciences (HUMS)🇮🇷Bandar Abbas, Hormozgan, Iran, Islamic Republic of